Harrington Robert Arthur 4

What Happened

• Robert Arthur Harrington, a director of Cytokinetics, received equity awards on 2026-05-27 totaling 7,152 shares: 2,851 shares reported as a direct award and 4,301 reported as a derivative award. Each line shows an acquisition price of $0.00, indicating these were grants/awards rather than purchases for cash.

Key Details

• Transaction date: 2026-05-27; reported on Form 4 filed 2026-05-27.
• Prices: $0.00 per share for both the direct award (2,851 shares) and the derivative award (4,301 shares); total cash paid reported = $0.
• Shares acquired total: 7,152 shares.
• Shares owned after transaction: not specified in the summary data provided here; see the full Form 4 for post-transaction ownership totals.
• Footnotes/plan info: none provided in the data supplied here (check the filed Form 4 for vesting schedules, plan references, or tax withholding).
• Timeliness: filing date matches the report date provided, which suggests the Form 4 was filed timely.

Context

• The "derivative" award likely represents equity units that vest or convert into common shares under plan terms (for example, restricted stock units or similar); these are not immediate open-market purchases or sales.
• Grants to directors are common as compensation/retention and do not by themselves indicate a buy/sell market signal. For full context (vesting, performance conditions, or sale restrictions) consult the complete Form 4 and company disclosures.